Immune responses to Clostridium difficile infection

Trends in Molecular Medicine

Volumn 18, Issue 11, 2012, Pages 658-666

  Madan, Rajat ^a   Petri Jr , William A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Antibiotic associated diarrhea; Chemokines; Immune response; Neutrophils; Pseudomembranous colitis; Toxic megacolon

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; ADHESIN; ANTIBIOTIC AGENT; BACTERIAL TOXIN; CALCITONIN; CASPASE RECRUITMENT DOMAIN PROTEIN 4; FIBRONECTIN BINDING PROTEIN; FIDAXOMICIN; GAMMA INTERFERON; HEME OXYGENASE 1; I KAPPA B; INFLAMMASOME; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 8; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; MECLINERTANT; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; RANTES; RHO FACTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANAEROBIC BACTERIUM; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE INFECTION; CYTOSKELETON; DENDRITIC CELL; DIARRHEA; ENTERITIS; EPITHELIUM CELL; GENE EXPRESSION; GENE LOCUS; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; MAST CELL DEGRANULATION; MICROFLORA; MUTAGENESIS; NONHUMAN; NONSENSE MUTATION; PATHOGENESIS; PROTEIN EXPRESSION; RECURRENT DISEASE; REVIEW; SCORING SYSTEM; VERO CELL;

ADAPTIVE IMMUNITY; ANIMALS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; COLON; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; VIRULENCE FACTORS;

CLOSTRIDIUM DIFFICILE;

EID: 84868203487     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.09.005     Document Type: Review

References (92)

1. Hall I.C., O'Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am. J. Dis. Child. 1935, 49:390-402.
2. Bartlett J.G., et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N. Engl. J. Med. 1978, 298:531-534.
3. Bartlett J.G., et al. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978, 75:778-782.
4. McDonald L.C., et al. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg. Infect. Dis. 2006, 12:409-415.
5. Miller B.A., et al. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect. Control Hosp. Epidemiol. 2011, 32:387-390.
6. Warny M., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366:1079-1084.
7. McDonald L.C., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 2005, 353:2433-2441.
8. Kuntz J.L., et al. Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC Infect. Dis. 2011, 11:194.
9. Khanna S., et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am. J. Gastroenterol. 2012, 107:89-95.
10. Deneve C., et al. New trends in Clostridium difficile virulence and pathogenesis. Int. J. Antimicrob. Agents 2009, 33(Suppl. 1):S24-S28.
11. Thibault A., et al. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. Infect. Control Hosp. Epidemiol. 1991, 12:345-348.
12. Owens R.C., et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin. Infect. Dis. 2008, 46(Suppl. 1):S19-S31.
13. Linsky A., et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch. Intern. Med. 2010, 170:772-778.
14. McFarland L.V., et al. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J. Infect. Dis. 1990, 162:678-684.
15. Loo V.G., et al. Host and pathogen factors for Clostridium difficile infection and colonization. N. Engl. J. Med. 2011, 365:1693-1703.
16. Bliss D.Z., et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann. Intern. Med. 1998, 129:1012-1019.
17. Kyne L., et al. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect. Control Hosp. Epidemiol. 2002, 23:653-659.
18. Cloud J., et al. Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clin. Gastroenterol. Hepatol. 2009, 7. 868-873.e2.
19. Muto C.A., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 2005, 26:273-280.
20. Freeman J., et al. The changing epidemiology of Clostridium difficile infections. Clin. Microbiol. Rev. 2010, 23:529-549.
21. Bulusu M., et al. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am. J. Gastroenterol. 2000, 95:3137-3141.
22. Fujitani S., et al. Comparison of clinical severity score indices for Clostridium difficile infection. Infect. Control Hosp. Epidemiol. 2011, 32:220-228.
23. Louie T.J., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 2011, 364:422-431.
24. Lo Vecchio A., Zacur G.M. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr. Opin. Gastroenterol. 2012, 28:1-9.
25. Loo V.G., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 2005, 353:2442-2449.
26. Pepin J., et al. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005, 173:1037-1042.
27. Pepin J., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 2005, 40:1591-1597.
28. Pepin J., et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am. J. Gastroenterol. 2007, 102:2781-2788.
29. Collignon A., et al. Heterogeneity of Clostridium difficile isolates from infants. Eur. J. Pediatr. 1993, 152:319-322.
30. Rousseau C., et al. Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition. J. Clin. Microbiol. 2011, 49:858-865.
31. Taylor N.S., et al. Comparison of two toxins produced by Clostridium difficile. Infect. Immun. 1981, 34:1036-1043.
32. Chang T.W., et al. Clostridium difficile toxin. Pharmacol. Ther. 1981, 13:441-452.
33. Kelly C.P., et al. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J. Clin. Invest. 1994, 93:1257-1265.
34. Voth D.E., Ballard J.D. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 2005, 18:247-263.
35. Kelly C.P., Kyne L. The host immune response to Clostridium difficile. J. Med. Microbiol. 2011, 60:1070-1079.
36. Qiu B., et al. Participation of reactive oxygen metabolites in Clostridium difficile toxin A-induced enteritis in rats. Am. J. Physiol. 1999, 276:G485-G490.
37. von Eichel-Streiber C., et al. Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol. Gen. Genet. 1992, 233:260-268.
38. Ryan A., et al. A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog. 2011, 7:e1002076.
39. Jarchum I., et al. Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect. Immun. 2011, 79:1498-1503.
40. Hasegawa M., et al. Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen. J. Immunol. 2011, 186:4872-4880.
41. Ng J., et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 2010, 139:542-552. 552.e1-e3.
42. Lyerly D.M., et al. Effects of Clostridium difficile toxins given intragastrically to animals. Infect. Immun. 1985, 47:349-352.
43. Lyras D., et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009, 458:1176-1179.
44. Kuehne S.A., et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467:711-713.
45. Carter G.P., et al. TcdB or not TcdB: a tale of two Clostridium difficile toxins. Future Microbiol. 2011, 6:121-123.
46. Carter G.P., et al. The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends Microbiol. 2012, 20:21-29.
47. Drudy D., et al. Toxin A-negative, toxin B-positive Clostridium difficile. Int. J. Infect. Dis. 2007, 11:5-10.
48. Carter G.P., et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog. 2011, 7:e1002317.
49. Schwan C., et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog. 2009, 5:e1000626.
50. Geric B., et al. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J. Infect. Dis. 2006, 193:1143-1150.
51. Bianco M., et al. Immunomodulatory activities of surface-layer proteins obtained from epidemic and hypervirulent Clostridium difficile strains. J. Med. Microbiol. 2011, 60:1162-1167.
52. Calabi E., et al. Molecular characterization of the surface layer proteins from Clostridium difficile. Mol. Microbiol. 2001, 40:1187-1199.
53. Calabi E., et al. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect. Immun. 2002, 70:5770-5778.
54. Pechine S., et al. Immunological properties of surface proteins of Clostridium difficile. J. Med. Microbiol. 2005, 54:193-196.
55. Sanchez-Hurtado K., et al. Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls. J. Med. Microbiol. 2008, 57:717-724.
56. Tasteyre A., et al. Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect. Immun. 2001, 69:7937-7940.
57. Mahida Y.R., et al. Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. Gut 1996, 38:337-347.
58. He D., et al. Clostridium difficile toxin A triggers human colonocyte IL-8 release via mitochondrial oxygen radical generation. Gastroenterology 2002, 122:1048-1057.
59. Kim J.M., et al. Differential expression and polarized secretion of CXC and CC chemokines by human intestinal epithelial cancer cell lines in response to Clostridium difficile toxin A. Microbiol. Immunol. 2002, 46:333-342.
60. Branka J.E., et al. Early functional effects of Clostridium difficile toxin A on human colonocytes. Gastroenterology 1997, 112:1887-1894.
61. Mahida Y.R., et al. Effect of Clostridium difficile toxin A on human colonic lamina propria cells: early loss of macrophages followed by T cell apoptosis. Infect. Immun. 1998, 66:5462-5469.
62. Dailey D.C., et al. Factors influencing the phagocytosis of Clostridium difficile by human polymorphonuclear leukocytes. Infect. Immun. 1987, 55:1541-1546.
63. Mykoniatis A., et al. Leptin mediates Clostridium difficile toxin A-induced enteritis in mice. Gastroenterology 2003, 124:683-691.
64. Ishida Y., et al. Essential involvement of IFN-γ in Clostridium difficile toxin A-induced enteritis. J. Immunol. 2004, 172:3018-3025.
65. Castagliuolo I., et al. Clostridium difficile toxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells. J. Immunol. 1998, 160:6039-6045.
66. Morteau O., et al. Genetic deficiency in the chemokine receptor CCR1 protects against acute Clostridium difficile toxin A enteritis in mice. Gastroenterology 2002, 122:725-733.
67. Garey K.W., et al. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin. Infect. Dis. 2010, 51:1406-1410.
68. Inui M., et al. Protective roles of CX3CR1-mediated signals in toxin A-induced enteritis through the induction of heme oxygenase-1 expression. J. Immunol. 2011, 186:423-431.
69. Meyer G.K., et al. Clostridium difficile toxins A and B directly stimulate human mast cells. Infect. Immun. 2007, 75:3868-3876.
70. Kurose I., et al. Clostridium difficile toxin A-induced microvascular dysfunction. Role of histamine. J. Clin. Invest. 1994, 94:1919-1926.
71. Wershil B.K., et al. Direct evidence of mast cell involvement in Clostridium difficile toxin A-induced enteritis in mice. Gastroenterology 1998, 114:956-964.
72. Sun X., et al. Essential role of the glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF-α by macrophages. Microb. Pathog. 2009, 46:298-305.
73. Warny M., et al. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J. Clin. Invest. 2000, 105:1147-1156.
74. Jefferson K.K., et al. Roles of intracellular calcium and NF-κB in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. J. Immunol. 1999, 163:5183-5191.
75. Castagliuolo I., et al. Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J. Clin. Invest. 1999, 103:843-849.
76. Anton P.M., et al. Corticotropin-releasing hormone (CRH) requirement in Clostridium difficile toxin A-mediated intestinal inflammation. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:8503-8508.
77. Kokkotou E., et al. Melanin-concentrating hormone (MCH) modulates C difficile toxin A-mediated enteritis in mice. Gut 2009, 58:34-40.
78. Castagliuolo I., et al. Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio cholerae enterotoxin in rat ileum. Gastroenterology 1994, 107:657-665.
79. Viscidi R., et al. Serum antibody response to toxins A and B of Clostridium difficile. J. Infect. Dis. 1983, 148:93-100.
80. Giannasca P.J., et al. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect. Immun. 1999, 67:527-538.
81. Lyerly D.M., et al. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect. Immun. 1991, 59:2215-2218.
82. Kyne L., et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 2000, 342:390-397.
83. Kyne L., et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357:189-193.
84. Leav B.A., et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010, 28:965-969.
85. Lowy I., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 2010, 362:197-205.
86. Babcock G.J., et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 2006, 74:6339-6347.
87. Pechine S., et al. Immunization of hamsters against Clostridium difficile infection using the Cwp84 protease as an antigen. FEMS Immunol. Med. Microbiol. 2011, 63:73-81.
88. Buffie C.G., et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect. Immun. 2012, 80:62-73.
89. Reeves A.E., et al. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2011, 2:145-158.
90. Sorg J.A., Sonenshein A.L. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J. Bacteriol. 2010, 192:4983-4990.
91. Giel J.L., et al. Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS ONE 2010, 5:e8740.
92. Gough E., et al. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 2011, 53:994-1002.